All In Biotech

Drug Trial Radar · NCT07764003

A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs

A Randomized, Double-blind, Phase II Study of Efficacy and Safety of TLL-018 in Moderate-to-Severe CSU Participants With Inadequate Response to Second-Generation H1 Antihistamines

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if different doses of TLL-018 works to treat in moderate-to-severe chronic spontaneous urticaria (CSU) participants . It will also learn about the safety of TLL-018. The main questions it aims to answer are: Which is the best regimen of TLL-018 administration in reducing or eliminating symptoms (hives, itch, and/or angioedema) ? What medical problems do participants have when taking TLL-018? Researchers will compare different doses of TLL-018, and placebo (a look-alike substance that contains no drug). Participants will: Take TLL-018 or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms

Conditions

  • Chronic Spontaneous Urticaria (CSU)

Interventions

  • TLL-018 tabletsDrug

    TLL-018 tablets taken orally 10 mg (1 tablet) twice daily

  • TLL-018 tabletsDrug

    TLL-018 tablets taken orally 20 mg (2 tablets) twice daily

  • PlaceboDrug

    Placebo taken orally (2 tablets) twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in weekly Itch Severity Score at Week 12Time frame: 12 weeks
  2. Change from baseline in weekly Urticaria Activity Score at Week 12Time frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.